One week after receiving a double win with US regulators, Takeda has secured approval in Europe for Entyvio (vedolizumab) in both its ulcerative colitis and Crohn's disease indications.
The European Commission has granted market authorization for Entyvio, a gut-selective humanized monoclonal antibody, for the treatment of adults with...
Welcome to Scrip
Create an account to read this article
Already a subscriber?